CTNI-43. COMBINATION OF TROFOSFAMIDE PLUS ETOPOSIDE IN RECURRENT ADULT-TYPE DIFFUSE GLIOMAS
نویسندگان
چکیده
Abstract Disease relapse almost inevitably occurs in patients with adult-type diffuse glioma. Standard of care treatment options at tumor are still not well defined. Few studies indicate that the combination trofosfamide plus etoposide (T/E) may be feasible pediatric glioblastoma patients. We collected clinicopathological data from adult glioma treated Trofosfamide (100mg/m2/day) and Etoposide (25mg/m2/day) for a minimum four weeks Division Clinical Neurooncology University Hospital Essen. T/E was administered orally “one week on, one off” scheme. A cohort receiving empiric investigators’ discretion balanced entity canonical prognostic factors served as control. toxicity it pertained to CTCAE (Common Terminology Criteria Adverse Events, version 5.0) survival explore putative efficacy.A total 33 were eligible this analysis. In IDH wild-type (n = 18) subgroup, median progression-free (3.8 months versus 2.9 months, HR: 2.09, 95% CI: 1.010-4.312, p 0.0227; PFS-6: 39% 6%) overall (10.4 5.7 3.05, 1.393-6.655, 0.0008) significantly prolonged compared control cohort. multivariable Cox regression analysis, emerged statistically significant marker regarding survival. observed high-grade adverse events (CTCAE grade III or higher) 21 (64%) all recurrent hematotoxicity comprising most 18, 86%; Lymphopenia: n=13, 62%). This study provides first indication is safe gliomas associated wildtype glioblastoma. Our provide reasonable rationale follow-up larger prospective controlled trial.
منابع مشابه
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
PURPOSE Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade ...
متن کاملCombination of Cyclophosphamide and Carboplatin in Recurrent Malignant Gliomas
Eventually, all patients with malignant gliomas recur or progress. Unfortunately, the optimal regimen in the salvage setting has not yet been defined. We retrospectively evaluated 52 patients with malignant gliomas who failed temozolomide therapy and were treated with a combination of intravenous carboplatin and oral cyclophosphamide. The median age of all patients, including those with gliobla...
متن کاملImpending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
BACKGROUND Progress in molecular oncology during the last decade has enabled investigators to more precisely define and group gliomas. The impacts of isocitrate dehydrogenase (IDH) mutation (mut) status and other molecular markers on the classification, prognostication, and management of diffuse gliomas are likely to be far-reaching. METHODS Clinical experience and the medical literature were...
متن کاملCurrent Management of Adult Diffuse Infiltrative Low Grade Gliomas.
Diffuse infiltrative low grade gliomas (LGG) account for approximately 15 % of all gliomas. The prognosis of LGG differs between high-risk and low-risk patients notwithstanding varying definitions of what constitutes a high-risk patient. Maximal safe resection optimally is the initial treatment. Surgery that achieves a large volume resection improves both progression-free and overall survival. ...
متن کاملDiffuse low-grade gliomas
Description : Diffuse low-grade gliomas (WHO grade II) are a sub-group of rare and heterogeneous primary brain tumors that usually occur in young patients living a normal life until the onset of a first seizure. A good understanding of the natural history of these gliomas namely: their steady progression, infiltration along white matter fibers and especially the risk of malignant transformation...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-oncology
سال: 2022
ISSN: ['1523-5866', '1522-8517']
DOI: https://doi.org/10.1093/neuonc/noac209.308